Last reviewed · How we verify

Università Vita-Salute San Raffaele — Portfolio Competitive Intelligence Brief

Università Vita-Salute San Raffaele pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
desflurane, isoflurane, sevoflurane desflurane, isoflurane, sevoflurane marketed
total intravenous anesthetics total intravenous anesthetics marketed GABA-A receptor agonist / General anesthetic GABA-A receptor Anesthesiology
Phosphocreatine Phosphocreatine phase 3 Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Università Vita-Salute San Raffaele:

Cite this brief

Drug Landscape (2026). Università Vita-Salute San Raffaele — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universit-vita-salute-san-raffaele. Accessed 2026-05-17.

Related